Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: A case series

Therapeutic Advances in Psychopharmacology

Volumn 4, Issue 3, 2014, Pages 117-122

  Lally, John ^a   Brook, Jennifer ^a   Dixon, Thomas ^a   Gaughran, Fiona ^b   Shergill, Sukhi ^b   Melikian, Narbeh ^b   Maccabe, James H ^c  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

clozapine; ivabradine; tachycardia; treatment resistant schizophrenia; blockers

Indexed keywords

EID: 84997966652     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125313512325     Document Type: Article

References (44)

1. Blomstrom-Lundqvist C. Scheinman M. Aliot E. Alpert J. Calkins H. Camm A. et al. (2003) ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias –executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol 42: 1493–1531.
2. BNF (2013) British National Formulary. 66th edition. London, UK: BMJ Group/Pharmaceutical Press.
3. Borer J. (2008) Heart rate: from risk marker to risk factor. Eur Heart J Suppl 10(Suppl. F): F2–F6.
4. Borer J. Fox K. Jaillon P. Lerebours G; for the Ivabradine Investigators Group (2003) Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107: 817–823.
5. Brown H. Difrancesco D. Noble S. (1979) How does adrenaline accelerate the heart? Nature 280: 235–236.
6. Buckley N. Sanders P. (2000) Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 23: 215–228.
7. Burton S. (2006) Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol 20(6 Suppl.): 6–19.
8. Camm A. Lau C. (2003) Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4: 83–89.
9. Cohen H. Loewenthal U. Matar M. Kotler M. (2001) Association of autonomic dysfunction and clozapine: heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry 179: 167–171.
10. Diaz A. Bourassa M. Guertin M. Tardif J. (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26: 967–974.
11. DiFrancesco D. (2006) Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 53: 399–406.
12. Ferrari R. (2009) A step further with ivabradine: SIGNIfY (Study assessing the morbidity–mortality benefits of the If inhibitor ivabradine in patients with coronary artery disease). Eur Heart J Suppl 11(Suppl. D): D19–D27.
13. Fox K. Ford I. Steg P. Tendera M. Ferrari R. (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372: 807–816.
14. Kannel W. Kannel C. Paffenbarger R. Jr Cupples L. (1987) Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113: 1489–1494.
15. Ko D. Hebert P. Coffey C. Sedrakyan A. Curtis J. Krumholz H. (2002) B-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 288: 351–357.
16. Leung J. Barr A. Procyshyn R. Honer W. Pang C. (2012) Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 135: 113–122.
17. Lieberman J. (1998) Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 3: 38–43.
18. Lieberman J. Kane J. Johns C. (1989) Clozapine: guidelines for clinical management. J Clin Psychiatry 50: 329–338.
19. Manz M. Reuter M. Lauck G. Omran H. Jung W. (2003) A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100: 149–155.
20. Marinkovic D. Timotijevic I. Babinski T. Totic S. Paunovic V. (1994) The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 18: 537–544.
21. McEvoy J. Lieberman J. Stroup T. Davis S. Meltzer H. Rosenheck R. et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610.
22. Meltzer H. (2005) Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J Clin Psychiatry 66: 530–533.
23. Merrill D. Dec G. Goff D. (2005) Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 25: 32–41.
24. Pai N. Vella S. (2012) Reason for clozapine cessation. Acta Psychiatr Scand 125: 39–44.
25. Ptaszynski P. Kaczmarek K. Ruta J. Klingenheben T. Wranicz J. (2013) Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace 15: 116–121.
26. Ragueneau I. Laveille C. Jochemsen R. Resplandy G. Funck-Brentano C. Jaillon P. (1998) Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 64: 192–203.
27. Ramahi T. (2000) Beta blocker therapy for chronic heart failure. Am Fam Physician 62: 2267–2274.
28. Riccioni G. (2011) Ivabradine: recent and potential applications in clinical practice. Exp Opin Pharmacother 12: 443–450.
29. Ronaldson K. Fitzgerald P. Taylor A. Topliss D. McNeil J. (2011) A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 45: 458–465.
30. Rosano G. Vitale C. Volterrani M. (2010) Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction. Adv Ther 27: 202–210.
31. Safferman A. Lieberman J. Kane J. Szymanski S. Kinon B. (1991) Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17: 247–261.
32. Sandoz I. (1987) Clozaril New Drug Application. East Hanover, NJ: Sandoz Pharmaceuticals Corp.
33. Shinbane J. Wood M. Jensen D. Ellenbogen K. Fitzpatrick A. Scheinman M. (1997) Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 29: 709–715.
34. Siris S. (2001) Suicide and schizophrenia. J Psychopharmacol 15: 127–135.
35. Speranza L. Franceschelli S. Riccioni G. (2012) The biological effects of ivabradine in cardiovascular disease. Molecules 17: 4924–4935.
36. Stryjer R. Timinsky I. Reznik I. Weizman A. Spivak B. (2009) Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. Clin Neuropharmacol 32: 290–292.
37. Sulfi S. Timmis A. (2006) Ivabradine – the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract 60: 222–228.
38. Swedberg K. Komajda M. Böhm M. Borer J. Ford I. Dubost-Brama A. et al. (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet 376: 875–885.
39. Tardif J. (2005) Clinical efficacy of ivabradine. Heart Drug 5: 25–28.
40. Tardif J. Ford I. Tendera M. Bourassa M. Fox K. (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26: 2529–2536.
41. Taylor D. Douglas-Hall P. Olofinjana B. Whiskey E. Thomas A. (2009) Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry 194: 165–167.
42. Wheeler A. Humberstone V. Robinson G. (2009) Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol 23: 957–965.
43. Wichterle D. (2013) Ivabradine for inappropriate sinus tachycardia: another piece of evidence. Europace 15: 9–10.
44. Young C. Bowers M. Jr Mazure C. (1998) Management of the adverse effects of clozapine. Schizophr Bull 24: 381–390.